Successful dose reduction of dupilumab in atopic dermatitis

Current UK, European and USA atopic dermatitis guidelines do not currently advise on the possibility of dose reduction of dupilumab therapy below the licensed dose of 300 mg subcutaneously every 2 weeks for adults. Here, we report preliminary findings to suggest that in those who respond well to the...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of dermatology (1951) Vol. 188; no. 5; pp. 678 - 679
Main Authors:	Ardern-Jones, Michael R, Buchanan, Emily E, Njungu, Samba, O'Driscoll, Daniel
Format:	Journal Article
Language:	English
Published:	England 20-04-2023
Subjects:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Dermatitis, Atopic - drug therapy Drug Tapering Humans Severity of Illness Index Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Current UK, European and USA atopic dermatitis guidelines do not currently advise on the possibility of dose reduction of dupilumab therapy below the licensed dose of 300 mg subcutaneously every 2 weeks for adults. Here, we report preliminary findings to suggest that in those who respond well to the licensed dose, dupilumab dosing can be reduced while maintaining good disease control. We propose a randomized controlled clinical trial to further analyse the cost effectiveness of this approach.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0007-0963 1365-2133
DOI:	10.1093/bjd/ljad011